QQ客服 官方微博 反馈留言

	Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
	Wang, Jing; Zhao, Yizhuo; Wang, Qiming; Zhang, Li; Shi, Jianhua; Wang, Zhehai; Cheng, Ying; He, Jianxing; Shi, Yuankai; Yu, Hao
刊名	CANCER BIOLOGY & MEDICINE
	2018
卷号	15期号:4
ISSN号	2095-3941
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3413215
专题	昆明医科大学
推荐引用方式 GB/T 7714	Wang, Jing,Zhao, Yizhuo,Wang, Qiming,et al. Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment[J]. CANCER BIOLOGY & MEDICINE,2018,15(4).
APA	Wang, Jing.,Zhao, Yizhuo.,Wang, Qiming.,Zhang, Li.,Shi, Jianhua.,...&Li, Kai.(2018).Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment.CANCER BIOLOGY & MEDICINE,15(4).
MLA	Wang, Jing,et al."Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment".CANCER BIOLOGY & MEDICINE 15.4(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。